In Oct 2007, the FDA declared that the labeling for all PDE5 inhibitors, including tadalafil, needs a much more outstanding warning from the possible risk of unexpected hearing decline as the result of publish-marketing reviews of non permanent deafness connected to use of PDE5 inhibitors.[19]Besides the information below, it is possible to see thi